CST6 and Miyoshi myopathy: Despite the fact that each of the 3 patients with MM had distinct percentages of CD138+ MM cells in bone marrow mononuclear cells (BMMCs), BCMA–CST6–CAR-T cell treatment significantly decreased the percentage of CD138+ cells in BMMC samples from all MM patients (Figure 3, B and C; P < 0.05).